A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

European Urology

Volumn 62, Issue 3, 2012, Pages 523-533

  Meeks, Joshua J ^a   Bellmunt, Joaquim ^b   Bochner, Bernard H ^a   Clarke, Noel W ^c   Daneshmand, Siamak ^d   Galsky, Matthew D ^e   Hahn, Noah M ^f   Lerner, Seth P ^g   Mason, Malcolm ^h   Powles, Thomas ⁱ   Sternberg, Cora N ^j   Sonpavde, Guru ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

Adjuvant therapy; Bladder cancer; Muscle invasive; Neoadjuvant therapy; Radical cystectomy; Urothelial cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; GEMCITABINE; IPILIMUMAB; METHOTREXATE; PACLITAXEL; SUNITINIB; VINBLASTINE;

AGE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; COMORBIDITY; CYSTECTOMY; DISEASE SEVERITY; DRUG EFFICACY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; MEDLINE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PATIENT ATTITUDE; PERIOPERATIVE PERIOD; PHYSICIAN ATTITUDE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; EVIDENCE-BASED MEDICINE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84864423349     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.048     Document Type: Review

References (65)

1. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
2. M.L. Quek, J.P. Stein, and P.E. Clark Natural history of surgically treated bladder carcinoma with extravesical tumor extension Cancer 98 2003 955 961
3. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414 2422 discussion 2422
4. M.P. Porter, M.C. Kerrigan, B.M. Donato, and S.D. Ramsey Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252 258
5. K.A. David, M.I. Milowsky, J. Ritchey, P.R. Carroll, and D.M. Nanus Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base J Urol 178 2007 451 454
6. A.T.J. Feifer, and M. Shouery Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder [abstract 240] J Clin Oncol 29 Suppl 7 2011
7. M. Ploeg, L.A. Kiemeney, and G.A. Smits Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy Urol Oncol 30 2012 247 251
8. R.S. Svatek, S.F. Shariat, and G. Novara Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort BJU Int 107 2011 898 904
9. P.I. Karakiewicz, S.F. Shariat, and G.S. Palapattu Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 2006 1254 1262
10. B.H. Bochner, M.W. Kattan, and K.C. Vora Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer J Clin Oncol 24 2006 3967 3972
11. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Nomograms provide improved accuracy for predicting survival after radical cystectomy Clin Cancer Res 12 2006 6663 6676
12. A.S. Kibel, F. Dehdashti, and M.D. Katz Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 27 2009 4314 4320
13. G. Swinnen, A. Maes, and H. Pottel FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer Eur Urol 57 2010 641 647
14. S.C. Smith, A.S. Baras, and G. Dancik A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment Lancet Oncol 12 2011 137 143
15. D.F. Bajorin, P.M. Dodd, and M. Mazumdar Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
16. H. von der Maase, S.W. Hansen, and J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
17. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
18. S.B. Saxman, K.J. Propert, and L.H. Einhorn Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 15 1997 2564 2569
19. J. Bellmunt, H. von der Maase, and G.M. Mead Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study [abstract LBA5030] J Clin Oncol 2007 25
20. M. De Santis, J. Bellmunt, and G. Mead Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy [EORTC Study 30986] J Clin Oncol 30 2009 191 199
21. M.D. Galsky, G.J. Chen, and W.K. Oh Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma Ann Oncol 23 2012 406 410
22. P.U. Malmström, E. Rintala, R. Wahlqvist, P. Hellström, S. Hellsten, and E. Hannisdal Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903 1906
23. A. Sherif, E. Rintala, and O. Mestad Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2 Scand J Urol Nephrol 36 2002 419 425
24. A. Sherif, L. Holmberg, and E. Rintala Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297 303
25. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial International collaboration of trialists Lancet 354 1999 533 540
26. G. Griffiths, R. Hall, R. Sylvester, D. Raghavan, and M.K. Parmar International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
27. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
28. G. Sonpavde, B.H. Goldman, and V.O. Speights Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
29. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 206 discussion 205-6
30. A. Dash, J.A. Pettus, and H.W. Herr A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477
31. C.J. Weight, J.A. Garcia, and D.E. Hansel Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
32. C. Blick, P. Hall, and T. Pwint Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle invasive transitional cell carcinoma of the bladder [abstract 235] J Clin Oncol 29 Suppl 7 2011
33. N. Mitra, P. Monk III, and K.S. Pohar Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (HD-MVAC) or gemcitabine and cisplatin (G-C) in muscle-invasive urothelial carcinoma of the bladder: a single-institution experience [abstract 280] J Clin Oncol 29 Suppl 7 2011
34. A.O. Siefker-Radtke, A.M. Kamat, and P.G. Corn Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M.D. Anderson Cancer Center [abstract 261] J Clin Oncol 30 Suppl 5 2012
35. S.F. Matin, V. Margulis, and A. Kamat Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma Cancer 116 2010 3127 3134
36. U.B. Chaudhary, A.R. Golshayan, and A. Brisendine Phase II trial of neoadjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder [abstract 276] J Clin Oncol 29 Suppl 7 2011
37. H. Abol-Enein, M. El-Mekresh, M. El-Baz, and M.A. Ghoneim Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomised study Br J Urol 79 Suppl 4 1997 174
38. J. Bellmunt, A. Ribas, and J. Albanell M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder Am J Clin Oncol 19 1996 344 348
39. R.W. deVere White, and P.N. Lara Jr. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group Trial (S0219) J Urol 181 2009 2476 2481
40. D.C. Smith, N.J. Mackler, and R.L. Dunn Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder J Urol 180 2008 2384 2388 discussion 2388
41. D.C. Smith, and G.P. Daignault A phase II trial of neoadjuvant ABI-007, carboplatin and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder [abstract 244] J Clin Oncol 29 Suppl 7 2011
42. H.W. Herr, J.R. Faulkner, and H.B. Grossman Surgical factors influence bladder cancer outcomes: a cooperative group report J Clin Oncol 22 2004 2781 2789
43. D.G. Skinner, J.R. Daniels, and C.A. Russell The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial J Urol 145 1991 459 464 discussion 464-7
44. M. Stockle, W. Meyenburg, and S. Wellek Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience J Urol 153 1995 47 52
45. J. Lehmann, L. Franzaring, J. Thuroff, S. Wellek, and M. Stockle Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer BJU Int 97 2006 42 47
46. F. Freiha, J. Reese, and F.M. Torti A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer J Urol. 155 1996 495 499 discussion 499-500
47. U.E. Studer, M. Bacchi, and C. Biedermann Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial J Urol 152 1994 81 84
48. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 189 201 discussion 199-201
49. R. Millikan, C. Dinney, and D. Swanson Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013
50. F. Cognetti, E.M. Ruggeri, and A. Felici Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial Ann Oncol 23 2012 695 700
51. L. Paz-Ares, E. Solsona, and E. Esteban Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study [abstract LBA4518] J Clin Oncol 28 Suppl 2010 18s
52. W.M. Stadler, S.P. Lerner, and S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
53. J. Lehmann, M. Retz, and C. Wiemers Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95) J Clin Oncol 23 2005 4963 4974
54. R.S.R. Svatek, S.F.S. Shariat, and R.E.R. Lasky The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder Clin Cancer Res 16 2010 4461 4467
55. D.F. Bajorin, and H.W. Herr Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift? J Clin Oncol 29 2011 2135 2137
56. S.M. Donat, A. Shabsigh, and C. Savage Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience Eur Urol 55 2009 177 186
57. R. Takata, T. Katagiri, and M. Kanehira Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clin Cancer Res 11 2005 2625 2636
58. R. Takata, T. Katagiri, and M. Kanehira Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy Cancer Sci 98 2007 113 117
59. A. Font, M. Taron, and J.L. Gago BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer Ann Oncol 22 2011 139 144
60. P.D. Williams, S. Cheon, and D.M. Havaleshko Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy Cancer Res 69 2009 8302 8309
61. X. Li, M.T. Lewis, and J. Huang Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 2008 672 679
62. A. Dash, M.D. Galsky, and A.J. Vickers Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506 513
63. C.I. Liakou, A. Kamat, and D.N. Tang CTLA-4 blockade increases IFNgamma-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients Proc Natl Acad Sci U S A. 105 2008 14987 14992
64. R.S. Pruthi, M. Nielsen, and S. Heathcote A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results BJU Int 106 2010 349 354
65. G. Sonpavde, M.M. Khan, and S.P. Lerner Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer J Urol 185 2011 456 461